BTIG Maintains Buy on LifeMD, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst David Larsen maintains a Buy rating on LifeMD (NASDAQ:LFMD) and raises the price target from $11 to $13.
March 15, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst David Larsen maintains a Buy rating on LifeMD and raises the price target from $11 to $13.
The increase in the price target by BTIG, along with the maintenance of a Buy rating, suggests a positive outlook on LifeMD's stock performance in the short term. This could lead to increased investor confidence and potentially drive the stock price up.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100